APR 08, 2022 9:29 AM PDT

Puberty-triggering Hormone Reverses Fatty Liver Disease in Mice

WRITTEN BY: Annie Lennon

Kisspeptin, a hormone that triggers puberty and regulates fertility in humans, may be able to treat non-alcoholic fatty liver disease. The corresponding study was published in The Journal of Clinical Investigation

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. Its prevalence has risen alongside that of obesity, type 2 diabetes, and metabolic syndrome. It usually begins with no symptoms however, over time, leads to inflammation resulting in non-alcoholic steatohepatitis (NASH). 

Fibrosis and cirrhosis then ensue until the liver becomes scarred and irreversibly damaged. Some with the condition develop liver cancer. Currently, no treatments have been approved to treat the condition. In the present study, researchers investigated the potential for kisspeptin to treat the condition.

To do so, they fed mice a high-fat, high-sugar diet to induce obesity and NAFLD. Those given the hormone, they noted, had less fat deposited in the liver, and were protected from developing NASH and fibrosis. The hormone also reversed more advanced stages of the disease. 

To understand how the hormone works, the researchers conducted another experiment in which they deleted the gene KISS1R, which encodes for kisspeptin, from liver cells. Afterward, they noticed that these cells no longer responded to kisspeptin and that mice fed a high-sugar, high-fat diet went on to develop fatty liver. 

"This work shows the kisspeptin receptor signaling pathway has a potential therapeutic role in NAFLD," said co-author of the study, Vinod K Rustgi, Director of Hepatology and a Distinguished Professor of Medicine at the Rutgers Robert Wood Johnson Medical School. 

"It does this by protecting against the development of fat in the liver and reducing inflammation and fibrosis. As such, it has the potential to favorably impact the health and lives of millions of patients around the globe,” he added. 

 

Sources: Science DailyThe Journal of Clinical Investigation

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
APR 20, 2022
Microbiology
Rapid AST: A key weapon in the fight against AMR
APR 20, 2022
Rapid AST: A key weapon in the fight against AMR
Despite the dire, well-documented risks of antimicrobial resistance (AMR), which threatens to kill 10 million people a y ...
MAY 15, 2022
Drug Discovery & Development
Implanted Insulin-producing Cells for Diabetes Treatment
MAY 15, 2022
Implanted Insulin-producing Cells for Diabetes Treatment
Type 1 diabetes, which affects about 9 to 10 million people globally, occurs when the immune system incorrectly identifi ...
MAY 19, 2022
Neuroscience
Daily Cranberry Consumption Boosts Cognitive Function, Reduces Cholesterol
MAY 19, 2022
Daily Cranberry Consumption Boosts Cognitive Function, Reduces Cholesterol
Eating a cup of cranberries per day may improve memory, ward off dementia and reduce ‘bad’ cholesterol in th ...
JUN 06, 2022
Drug Discovery & Development
Weight loss Surgery Reduces Cancer Risk and Cancer Deaths
JUN 06, 2022
Weight loss Surgery Reduces Cancer Risk and Cancer Deaths
Weight loss achieved via bariatric surgery among adults with obesity is linked to a lower risk of developing cancer and ...
JUN 09, 2022
Cardiology
Supplements and Heart Health
JUN 09, 2022
Supplements and Heart Health
There is little evidence that supplements actually improve heart health.
JUN 19, 2022
Drug Discovery & Development
Oral Immunotherapy for Peanut Allergy Most Effective Before 12 Months Old
JUN 19, 2022
Oral Immunotherapy for Peanut Allergy Most Effective Before 12 Months Old
Oral immunotherapy for peanut allergies is safer and more effective in children under 12 months old than in toddlers and ...
Loading Comments...